Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 4495 | 11.54 |
09:34 ET | 4474 | 11.4 |
09:38 ET | 500 | 11.37 |
09:39 ET | 1250 | 11.27 |
09:41 ET | 4277 | 11.26 |
09:43 ET | 36511 | 11.3 |
09:45 ET | 9881 | 11.27 |
09:48 ET | 1300 | 11.22 |
09:50 ET | 2390 | 11.25 |
09:52 ET | 100 | 11.28 |
09:54 ET | 664 | 11.25 |
09:56 ET | 29105 | 11.25 |
09:57 ET | 3787 | 11.27 |
09:59 ET | 2417 | 11.26 |
10:01 ET | 200 | 11.27 |
10:03 ET | 1775 | 11.25 |
10:06 ET | 1500 | 11.295 |
10:08 ET | 1100 | 11.26 |
10:12 ET | 500 | 11.265 |
10:14 ET | 1503 | 11.29 |
10:15 ET | 1201 | 11.316 |
10:17 ET | 600 | 11.32 |
10:19 ET | 2586 | 11.34 |
10:21 ET | 500 | 11.34 |
10:24 ET | 910 | 11.3 |
10:26 ET | 25316 | 11.305 |
10:28 ET | 5127 | 11.3 |
10:30 ET | 874 | 11.34 |
10:35 ET | 200 | 11.33 |
10:37 ET | 300 | 11.35 |
10:39 ET | 1100 | 11.4 |
10:42 ET | 786 | 11.43 |
10:44 ET | 4930 | 11.42 |
10:46 ET | 1685 | 11.45 |
10:50 ET | 200 | 11.45 |
10:51 ET | 1700 | 11.41 |
10:53 ET | 700 | 11.38 |
10:55 ET | 100 | 11.36 |
10:57 ET | 203 | 11.34 |
11:00 ET | 300 | 11.34 |
11:02 ET | 3887 | 11.445 |
11:04 ET | 100 | 11.45 |
11:06 ET | 225 | 11.47 |
11:08 ET | 2977 | 11.54 |
11:09 ET | 4000 | 11.51 |
11:11 ET | 100 | 11.51 |
11:13 ET | 200 | 11.5 |
11:15 ET | 1407 | 11.54 |
11:18 ET | 1200 | 11.52 |
11:20 ET | 400 | 11.51 |
11:24 ET | 400 | 11.5 |
11:26 ET | 600 | 11.48 |
11:27 ET | 2300 | 11.44 |
11:29 ET | 740 | 11.44 |
11:31 ET | 740 | 11.445 |
11:33 ET | 300 | 11.44 |
11:36 ET | 100 | 11.445 |
11:38 ET | 100 | 11.44 |
11:40 ET | 100 | 11.445 |
11:42 ET | 300 | 11.45 |
11:44 ET | 200 | 11.445 |
11:45 ET | 1685 | 11.49 |
11:47 ET | 400 | 11.51 |
11:49 ET | 1305 | 11.467 |
11:51 ET | 300 | 11.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 413.4M | -3.2x | --- |
Neurogene Inc | 420.6M | -7.2x | --- |
Terns Pharmaceuticals Inc | 383.5M | -4.9x | --- |
Anavex Life Sciences Corp | 380.9M | -8.7x | --- |
ACELYRIN Inc | 447.6M | -1.7x | --- |
Annexon Inc | 451.0M | -3.4x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $413.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.